List of Tables
    Table 1. Urological Cancer Therapeutics Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Urological Cancer Therapeutics Drugs Market Trends
    Table 3. Urological Cancer Therapeutics Drugs Market Drivers
    Table 4. Urological Cancer Therapeutics Drugs Market Challenges
    Table 5. Urological Cancer Therapeutics Drugs Market Restraints
    Table 6. Global Urological Cancer Therapeutics Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Urological Cancer Therapeutics Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Urological Cancer Therapeutics Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Urological Cancer Therapeutics Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Urological Cancer Therapeutics Drugs Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Urological Cancer Therapeutics Drugs Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Urological Cancer Therapeutics Drugs Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Urological Cancer Therapeutics Drugs Sales by Manufacturer, (K MT), 2017-2022
    Table 14. Global Urological Cancer Therapeutics Drugs Sales Share by Manufacturer, 2017-2022
    Table 15. Global Urological Cancer Therapeutics Drugs Price by Manufacturer (2017-2022) & (USD/MT)
    Table 16. Global Urological Cancer Therapeutics Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Urological Cancer Therapeutics Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2021)
    Table 18. Top Players of Urological Cancer Therapeutics Drugs in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Urological Cancer Therapeutics Drugs Product Type
    Table 20. Date of International Manufacturers Enter into Urological Cancer Therapeutics Drugs Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Urological Cancer Therapeutics Drugs Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Urological Cancer Therapeutics Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Urological Cancer Therapeutics Drugs Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Urological Cancer Therapeutics Drugs Sales by Players, (K MT), 2020, 2021 & 2022
    Table 26. United States Urological Cancer Therapeutics Drugs Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Urological Cancer Therapeutics Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Urological Cancer Therapeutics Drugs Sales in Volume by Region (2017-2022) & (K MT)
    Table 29. Global Urological Cancer Therapeutics Drugs Sales in Volume Forecast by Region (2023-2028) & (K MT)
    Table 30. Global Urological Cancer Therapeutics Drugs Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Urological Cancer Therapeutics Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Urological Cancer Therapeutics Drugs Sales in Volume by Country (2017-2028) & (K MT)
    Table 33. North America Urological Cancer Therapeutics Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Urological Cancer Therapeutics Drugs Sales in Volume by Region (2017-2028) & (K MT)
    Table 35. Asia Pacific Urological Cancer Therapeutics Drugs Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Urological Cancer Therapeutics Drugs Sales in Volume by Country (2017-2028) & (K MT)
    Table 37. Europe Urological Cancer Therapeutics Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Urological Cancer Therapeutics Drugs Sales in Volume by Country (2017-2028) & (K MT)
    Table 39. Latin Americaa Urological Cancer Therapeutics Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Urological Cancer Therapeutics Drugs Sales in Volume by Country (2017-2028) & (K MT)
    Table 41. Middle East and Africa Urological Cancer Therapeutics Drugs Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Novartis Corporation Information
    Table 43. Novartis Description and Business Overview
    Table 44. Novartis Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 45. Novartis Urological Cancer Therapeutics Drugs Product
    Table 46. Novartis Recent Development
    Table 47. Pfizer Corporation Information
    Table 48. Pfizer Description and Business Overview
    Table 49. Pfizer Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 50. Pfizer Product
    Table 51. Pfizer Recent Development
    Table 52. Johnson & Johnson Corporation Information
    Table 53. Johnson & Johnson Description and Business Overview
    Table 54. Johnson & Johnson Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 55. Johnson & Johnson Product
    Table 56. Johnson & Johnson Recent Development
    Table 57. AstraZeneca Corporation Information
    Table 58. AstraZeneca Description and Business Overview
    Table 59. AstraZeneca Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 60. AstraZeneca Product
    Table 61. AstraZeneca Recent Development
    Table 62. Astellas Corporation Information
    Table 63. Astellas Description and Business Overview
    Table 64. Astellas Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 65. Astellas Product
    Table 66. Astellas Recent Development
    Table 67. Bristol-Myers Squibb Corporation Information
    Table 68. Bristol-Myers Squibb Description and Business Overview
    Table 69. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 70. Bristol-Myers Squibb Product
    Table 71. Bristol-Myers Squibb Recent Development
    Table 72. Abbott Laboratories Corporation Information
    Table 73. Abbott Laboratories Description and Business Overview
    Table 74. Abbott Laboratories Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 75. Abbott Laboratories Product
    Table 76. Abbott Laboratories Recent Development
    Table 77. Celgene Corporation Corporation Information
    Table 78. Celgene Corporation Description and Business Overview
    Table 79. Celgene Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 80. Celgene Corporation Product
    Table 81. Celgene Corporation Recent Development
    Table 82. Dendreon Corporation Corporation Information
    Table 83. Dendreon Corporation Description and Business Overview
    Table 84. Dendreon Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 85. Dendreon Corporation Product
    Table 86. Dendreon Corporation Recent Development
    Table 87. Ferring Pharmaceuticals Corporation Information
    Table 88. Ferring Pharmaceuticals Description and Business Overview
    Table 89. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 90. Ferring Pharmaceuticals Product
    Table 91. Ferring Pharmaceuticals Recent Development
    Table 92. GlaxoSmithKline plc Corporation Information
    Table 93. GlaxoSmithKline plc Description and Business Overview
    Table 94. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 95. GlaxoSmithKline plc Product
    Table 96. GlaxoSmithKline plc Recent Development
    Table 97. Indevus Pharmaceuticals Inc Corporation Information
    Table 98. Indevus Pharmaceuticals Inc Description and Business Overview
    Table 99. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 100. Indevus Pharmaceuticals Inc Product
    Table 101. Indevus Pharmaceuticals Inc Recent Development
    Table 102. Ipsen Corporation Information
    Table 103. Ipsen Description and Business Overview
    Table 104. Ipsen Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 105. Ipsen Product
    Table 106. Ipsen Recent Development
    Table 107. Roche Healthcare Corporation Information
    Table 108. Roche Healthcare Description and Business Overview
    Table 109. Roche Healthcare Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 110. Roche Healthcare Product
    Table 111. Roche Healthcare Recent Development
    Table 112. Sanofi S.A. Corporation Information
    Table 113. Sanofi S.A. Description and Business Overview
    Table 114. Sanofi S.A. Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
    Table 115. Sanofi S.A. Product
    Table 116. Sanofi S.A. Recent Development
    Table 117. Key Raw Materials Lists
    Table 118. Raw Materials Key Suppliers Lists
    Table 119. Urological Cancer Therapeutics Drugs Customers List
    Table 120. Urological Cancer Therapeutics Drugs Distributors List
    Table 121. Research Programs/Design for This Report
    Table 122. Key Data Information from Secondary Sources
    Table 123. Key Data Information from Primary Sources
List of Figures
    Figure 1. Urological Cancer Therapeutics Drugs Product Picture
    Figure 2. Global Urological Cancer Therapeutics Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Urological Cancer Therapeutics Drugs Market Size 2017-2028 (US$ Million)
    Figure 4. Global Urological Cancer Therapeutics Drugs Sales 2017-2028 (K MT)
    Figure 5. United States Urological Cancer Therapeutics Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Urological Cancer Therapeutics Drugs Market Size 2017-2028 (US$ Million)
    Figure 7. United States Urological Cancer Therapeutics Drugs Sales 2017-2028 (K MT)
    Figure 8. United States Urological Cancer Therapeutics Drugs Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Urological Cancer Therapeutics Drugs Market Share in Global, in Volume (K MT) 2017-2028
    Figure 10. Urological Cancer Therapeutics Drugs Report Years Considered
    Figure 11. Product Picture of Xofigo (radium Ra 223 dichloride)
    Figure 12. Product Picture of Jevtana (cabazitaxel)
    Figure 13. Product Picture of Inlyta (axitinib)
    Figure 14. Product Picture of Votrient (pazopanib hydrochloride)
    Figure 15. Product Picture of Sutent (sunitinib malate)
    Figure 16. Product Picture of Zytiga (abiraterone acetate)
    Figure 17. Product Picture of Xtandi (enzalutamide)
    Figure 18. Product Picture of Opdivo (nivolumab)
    Figure 19. Product Picture of Provenge (sipuleucel-T)
    Figure 20. Global Urological Cancer Therapeutics Drugs Market Share by Type in 2022 & 2028
    Figure 21. Global Urological Cancer Therapeutics Drugs Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 22. Global Urological Cancer Therapeutics Drugs Sales Market Share in Value by Type (2017-2028)
    Figure 23. Global Urological Cancer Therapeutics Drugs Sales by Type (2017-2028) & (K MT)
    Figure 24. Global Urological Cancer Therapeutics Drugs Sales Market Share in Volume by Type (2017-2028)
    Figure 25. Global Urological Cancer Therapeutics Drugs Price by Type (2017-2028) & (USD/MT)
    Figure 26. United States Urological Cancer Therapeutics Drugs Market Share by Type in 2022 & 2028
    Figure 27. United States Urological Cancer Therapeutics Drugs Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 28. United States Urological Cancer Therapeutics Drugs Sales Market Share in Value by Type (2017-2028)
    Figure 29. United States Urological Cancer Therapeutics Drugs Sales by Type (2017-2028) & (K MT)
    Figure 30. United States Urological Cancer Therapeutics Drugs Sales Market Share in Volume by Type (2017-2028)
    Figure 31. United States Urological Cancer Therapeutics Drugs Price by Type (2017-2028) & (USD/MT)
    Figure 32. Product Picture of Hospital
    Figure 33. Product Picture of Medical Research Laboratory
    Figure 34. Product Picture of Others
    Figure 35. Global Urological Cancer Therapeutics Drugs Market Share by Application in 2022 & 2028
    Figure 36. Global Urological Cancer Therapeutics Drugs Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 37. Global Urological Cancer Therapeutics Drugs Sales Market Share in Value by Application (2017-2028)
    Figure 38. Global Urological Cancer Therapeutics Drugs Sales by Application (2017-2028) & (K MT)
    Figure 39. Global Urological Cancer Therapeutics Drugs Sales Market Share in Volume by Application (2017-2028)
    Figure 40. Global Urological Cancer Therapeutics Drugs Price by Application (2017-2028) & (USD/MT)
    Figure 41. United States Urological Cancer Therapeutics Drugs Market Share by Application in 2022 & 2028
    Figure 42. United States Urological Cancer Therapeutics Drugs Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 43. United States Urological Cancer Therapeutics Drugs Sales Market Share in Value by Application (2017-2028)
    Figure 44. United States Urological Cancer Therapeutics Drugs Sales by Application (2017-2028) & (K MT)
    Figure 45. United States Urological Cancer Therapeutics Drugs Sales Market Share in Volume by Application (2017-2028)
    Figure 46. United States Urological Cancer Therapeutics Drugs Price by Application (2017-2028) & (USD/MT)
    Figure 47. North America Urological Cancer Therapeutics Drugs Sales in Volume Growth Rate 2017-2028 (K MT)
    Figure 48. North America Urological Cancer Therapeutics Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 49. U.S. Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Canada Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Europe Urological Cancer Therapeutics Drugs Sales in Volume Growth Rate 2017-2028 (K MT)
    Figure 52. Europe Urological Cancer Therapeutics Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 53. Germany Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 54. France Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 55. U.K. Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Italy Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 57. Russia Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. Asia-Pacific Urological Cancer Therapeutics Drugs Sales in Volume Growth Rate 2017-2028 (K MT)
    Figure 59. Asia-Pacific Urological Cancer Therapeutics Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 60. China Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. Japan Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. South Korea Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. India Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Australia Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. China Taiwan Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 66. Indonesia Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 67. Thailand Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Malaysia Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 69. Latin America Urological Cancer Therapeutics Drugs Sales in Volume Growth Rate 2017-2028 (K MT)
    Figure 70. Latin America Urological Cancer Therapeutics Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 71. Mexico Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 72. Brazil Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. Argentina Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 74. Middle East & Africa Urological Cancer Therapeutics Drugs Sales in Volume Growth Rate 2017-2028 (K MT)
    Figure 75. Middle East & Africa Urological Cancer Therapeutics Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 76. Turkey Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 77. Saudi Arabia Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 78. UAE Urological Cancer Therapeutics Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 79. Urological Cancer Therapeutics Drugs Value Chain
    Figure 80. Urological Cancer Therapeutics Drugs Production Process
    Figure 81. Channels of Distribution
    Figure 82. Distributors Profiles
    Figure 83. Bottom-up and Top-down Approaches for This Report
    Figure 84. Data Triangulation
    Figure 85. Key Executives Interviewed